ValiRx PLC Notification of US Patent Allowance (2470T)
October 11 2017 - 2:00AM
UK Regulatory
TIDMVAL
RNS Number : 2470T
ValiRx PLC
11 October 2017
VALIRX PLC
("ValiRx", the "Company" or the "Group")
NOTIFICATION OF US PATENT ALLOWANCE
FOR THERAPEUTIC COMPOUND, VAL401
London, UK., 11 October 2017: ValiRx Plc (AIM: VAL), the
clinical stage biotechnology company, is pleased to report that
ValiSeek Limited ("ValiSeek"), the joint venture between ValiRx and
Tangent Reprofiling Limited ("Tangent"), announces a new US patent
allowance and an update on its patent portfolio. The clinical stage
therapeutic compound VAL401 has recently completed dosing in Phase
II clinical trials to treat patients with lung cancer. ValiSeek was
formed to progress VAL401 into Clinical trials for the treatment of
lung cancer and other oncology indications.
Notification of a Fifth US Patent Allowance for VAL401
ValiSeek has received notification that a further
method-of-treatment patent has been allowed by the US Patent Office
covering the use of VAL401 in the treatment of prostate
adenocarcinoma. The table below provides details of patents in the
VAL401 portfolio that have been either fully granted or allowed.
International patents are pending across Europe, Asia, Australasia
and in North and South America, providing coverage in all
significant markets worldwide.
Dr Suzy Dilly, CEO of ValiSeek, commented: "It is really
pleasing to receive this notification of allowance for this latest
VAL401 patent so close on the heels after our encouraging and
positive announcement of first verified clinical data emerging from
the VAL401 trial in Tbilisi, Georgia. This allowance will further
strengthen ValiSeek's portfolio at an important time in our
development pathway and will grow the confidence of existing and
potential partners, as far as bringing this compound closer to the
marketplace".
Country Patent number Date Filed Date Granted/Allowed
-------------- ---------------- ------------- ---------------------
United States US 9072743 26 September 07 July 2015
2013
-------------- ---------------- ------------- ---------------------
United States US 9375433 08 May 2015 28 June 2016
-------------- ---------------- ------------- ---------------------
United States US 9585887 27 May 2015 07 March 2017
-------------- ---------------- ------------- ---------------------
United States US 9585890 31 May 2016 07 March 2017
-------------- ---------------- ------------- ---------------------
United States To be allocated 27 February Allowed
shortly 2017
-------------- ---------------- ------------- ---------------------
Australia AU 2013322612 26 September 14 September
2013 2017
-------------- ---------------- ------------- ---------------------
New Zealand NZ 706067 26 September 01 November
2013 2016
-------------- ---------------- ------------- ---------------------
This announcement contains inside information for the purposes
of Article 7 of EU Regulation 596/2014.
*** ENDS ***
For more information, please contact:
ValiRx plc Tel: +44 (0) 20
3008 4416
www.valirx.com
Dr Satu Vainikka, Chief Executive Tel: +44 (0) 20
3008 4416
Tarquin Edwards, Head of Communications. Tel: +44 (0) 7879
458 364
tarquin.edwards@valirx.com
Cairn Financial Advisers LLP Tel: +44 (0) 20
(Nominated Adviser) 7213 0880
Liam Murray/Jo Turner/Richard
Nash
Beaufort Securities Limited Tel: +44 (0) 207
(Broker) 382 8300
Jon Belliss
Notes for Editors
About ValiSeek
ValiSeek Limited ("ValiSeek") is a joint venture ("JV") company
between ValiRx Plc and Tangent Reprofiling Limited, part of the
SEEK Group. ValiSeek was formed to progress the drug VAL401 through
its remaining preclinical development and towards Phase II trials
for the treatment of lung cancer and other oncology
indications.
About ValiRx
ValiRx is a biotechnology oncology focused company specialising
in developing novel treatments for cancer and associated
biomarkers. It aims to make a significant contribution in
"precision" medicine and science, namely to engineer a breakthrough
into human health and well-being, through the early detection of
cancer and its therapeutic intervention.
The Company's business model focuses on out-licensing
therapeutic candidates early in the development process. By aiming
for early-stage value creation, the company reduces risk
considerably while increasing the potential for realising value.
The group is already in licensing discussions with major players in
the oncology field.
ValiRx's two classes of drugs in development, which each have
the potential for meeting hitherto unmet medical needs by existing
methods, have worldwide patent filings and agreed commercial
rights. They originate or derive from World class institutions,
such as Cancer Research UK and Imperial College.
Until recently, cancer treatments relied on non-specific agents,
such as chemotherapy. With the development of target-based agents,
primed to attack cancer cells only, less toxic and more effective
treatments are now possible. New drugs in this group-such as those
in ValiRx's pipeline-promise to greatly improve outcomes for cancer
patients.
The Company listed on the AIM Market of the London Stock
Exchange in October 2006 and trades under the ticker symbol:
VAL
This information is provided by RNS
The company news service from the London Stock Exchange
END
RESQBLFFDBFXFBD
(END) Dow Jones Newswires
October 11, 2017 02:00 ET (06:00 GMT)
Valirx (LSE:VAL)
Historical Stock Chart
From Apr 2024 to May 2024
Valirx (LSE:VAL)
Historical Stock Chart
From May 2023 to May 2024
